{
  "id": [
    "32544799"
  ],
  "source": [
    "MED"
  ],
  "pmid": [
    "32544799"
  ],
  "pmcid": [
    "PMC7269953"
  ],
  "doi": [
    "10.1016/j.ejca.2020.05.026"
  ],
  "title": [
    "Immune checkpoint inhibitors: a physiology-driven approach to the treatment of coronavirus disease 2019."
  ],
  "authorString": [
    "Di Cosimo S, Malfettone A, Pérez-García JM, Llombart-Cussac A, Miceli R, Curigliano G, Cortés J."
  ],
  "authorList": [
    {
      "author": [
        {
          "fullName": [
            "Di Cosimo S"
          ],
          "firstName": [
            "Serena"
          ],
          "lastName": [
            "Di Cosimo"
          ],
          "initials": [
            "S"
          ],
          "authorAffiliationsList": [
            {
              "authorAffiliation": [
                "Biomarker Unit, Department of Applied Research and Technological Development, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milano, Italy."
              ]
            }
          ]
        },
        {
          "fullName": [
            "Malfettone A"
          ],
          "firstName": [
            "Andrea"
          ],
          "lastName": [
            "Malfettone"
          ],
          "initials": [
            "A"
          ],
          "authorAffiliationsList": [
            {
              "authorAffiliation": [
                "Medica Scientia Innovation Research (MedSIR), Ridgewood, NJ, USA and Barcelona, Spain."
              ]
            }
          ]
        },
        {
          "fullName": [
            "Pérez-García JM"
          ],
          "firstName": [
            "José M"
          ],
          "lastName": [
            "Pérez-García"
          ],
          "initials": [
            "JM"
          ],
          "authorAffiliationsList": [
            {
              "authorAffiliation": [
                "Medica Scientia Innovation Research (MedSIR), Ridgewood, NJ, USA and Barcelona, Spain; IOB Institute of Oncology, Quironsalud Group, Madrid and Barcelona, Spain."
              ]
            }
          ]
        },
        {
          "fullName": [
            "Llombart-Cussac A"
          ],
          "firstName": [
            "Antonio"
          ],
          "lastName": [
            "Llombart-Cussac"
          ],
          "initials": [
            "A"
          ],
          "authorAffiliationsList": [
            {
              "authorAffiliation": [
                "Medica Scientia Innovation Research (MedSIR), Ridgewood, NJ, USA and Barcelona, Spain; Hospital Arnau de Vilanova, Universidad Católica de Valencia San Vicente Mártir, Valencia, Spain."
              ]
            }
          ]
        },
        {
          "fullName": [
            "Miceli R"
          ],
          "firstName": [
            "Rosalba"
          ],
          "lastName": [
            "Miceli"
          ],
          "initials": [
            "R"
          ],
          "authorAffiliationsList": [
            {
              "authorAffiliation": [
                "Department of Clinical Epidemiology and Trial Organization, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milano, Italy."
              ]
            }
          ]
        },
        {
          "fullName": [
            "Curigliano G"
          ],
          "firstName": [
            "Giuseppe"
          ],
          "lastName": [
            "Curigliano"
          ],
          "initials": [
            "G"
          ],
          "authorAffiliationsList": [
            {
              "authorAffiliation": [
                "Istituto Europeo di Oncologia, IRCCS, Milano, Italy; University of Milano, School of Medicine, Milano, Italy."
              ]
            }
          ]
        },
        {
          "fullName": [
            "Cortés J"
          ],
          "firstName": [
            "Javier"
          ],
          "lastName": [
            "Cortés"
          ],
          "initials": [
            "J"
          ],
          "authorAffiliationsList": [
            {
              "authorAffiliation": [
                "Medica Scientia Innovation Research (MedSIR), Ridgewood, NJ, USA and Barcelona, Spain; IOB Institute of Oncology, Quironsalud Group, Madrid and Barcelona, Spain; Vall D´Hebron Institute of Oncology (VHIO), Barcelona, Spain. Electronic address: jacortes@vhio.net."
              ]
            }
          ]
        }
      ]
    }
  ],
  "dataLinksTagsList": [
    {
      "dataLinkstag": [
        "supporting_data",
        "altmetrics"
      ]
    }
  ],
  "journalInfo": [
    {
      "volume": [
        "135"
      ],
      "journalIssueId": [
        "2966966"
      ],
      "dateOfPublication": [
        "2020 Jun"
      ],
      "monthOfPublication": [
        "6"
      ],
      "yearOfPublication": [
        "2020"
      ],
      "printPublicationDate": [
        "2020-06-01"
      ],
      "journal": [
        {
          "title": [
            "European journal of cancer (Oxford, England : 1990)"
          ],
          "ISOAbbreviation": [
            "Eur. J. Cancer"
          ],
          "medlineAbbreviation": [
            "Eur J Cancer"
          ],
          "NLMid": [
            "9005373"
          ],
          "ISSN": [
            "1879-0852"
          ],
          "ESSN": [
            "1879-0852"
          ]
        }
      ]
    }
  ],
  "pubYear": [
    "2020"
  ],
  "pageInfo": [
    "62-65"
  ],
  "abstractText": [
    "Although confirmed cases of the deadly coronavirus disease 2019 (COVID-19) have exceeded 4.7 million globally, scientists are pushing forward with efforts to develop vaccines and treatments in an attempt to slow the pandemic and lessen the disease's damage. Although no proven effective therapies for treating patients with COVID-19 or for managing their complications currently exist, the rapidly expanding knowledge regarding severe acute respiratory syndrome coronavirus 2 and its interplay with hosts provides a significant number of potential drug targets and the potential to repurpose drugs already tested in other diseases. Herein, we report the biological rationale of immune-activating drugs and a brief summary of literature data on the potential therapeutic value of immune checkpoint inhibitors that have been recently tested beyond cancer treatment for their potential to restore cellular immunocompetence."
  ],
  "affiliation": [
    "Biomarker Unit, Department of Applied Research and Technological Development, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milano, Italy."
  ],
  "publicationStatus": [
    "aheadofprint"
  ],
  "language": [
    "eng"
  ],
  "pubModel": [
    "Print-Electronic"
  ],
  "pubTypeList": [
    {
      "pubType": [
        "research-article",
        "Journal Article"
      ]
    }
  ],
  "keywordList": [
    {
      "keyword": [
        "Tocilizumab",
        "Cytokine Storm",
        "Anti–pd-1",
        "Pembrolizumab",
        "Covid-19",
        "Sars-cov-2",
        "Anti–il-6r"
      ]
    }
  ],
  "subsetList": [
    {
      "subset": [
        {
          "code": [
            "IM"
          ],
          "name": [
            "Index Medicus"
          ]
        }
      ]
    }
  ],
  "fullTextUrlList": [
    {
      "fullTextUrl": [
        {
          "availability": [
            "Subscription required"
          ],
          "availabilityCode": [
            "S"
          ],
          "documentStyle": [
            "doi"
          ],
          "site": [
            "DOI"
          ],
          "url": [
            "https://doi.org/10.1016/j.ejca.2020.05.026"
          ]
        },
        {
          "availability": [
            "Open access"
          ],
          "availabilityCode": [
            "OA"
          ],
          "documentStyle": [
            "html"
          ],
          "site": [
            "Europe_PMC"
          ],
          "url": [
            "https://europepmc.org/articles/PMC7269953"
          ]
        },
        {
          "availability": [
            "Open access"
          ],
          "availabilityCode": [
            "OA"
          ],
          "documentStyle": [
            "pdf"
          ],
          "site": [
            "Europe_PMC"
          ],
          "url": [
            "https://europepmc.org/articles/PMC7269953?pdf=render"
          ]
        },
        {
          "availability": [
            "Open access"
          ],
          "availabilityCode": [
            "OA"
          ],
          "documentStyle": [
            "doi"
          ],
          "site": [
            "DOI"
          ],
          "url": [
            "https://doi.org/10.1016/j.ejca.2020.05.026"
          ]
        }
      ]
    }
  ],
  "isOpenAccess": [
    "Y"
  ],
  "inEPMC": [
    "Y"
  ],
  "inPMC": [
    "N"
  ],
  "hasPDF": [
    "Y"
  ],
  "hasBook": [
    "N"
  ],
  "hasSuppl": [
    "N"
  ],
  "citedByCount": [
    "0"
  ],
  "hasData": [
    "Y"
  ],
  "hasReferences": [
    "N"
  ],
  "hasTextMinedTerms": [
    "Y"
  ],
  "hasDbCrossReferences": [
    "N"
  ],
  "hasLabsLinks": [
    "Y"
  ],
  "authMan": [
    "N"
  ],
  "epmcAuthMan": [
    "N"
  ],
  "nihAuthMan": [
    "N"
  ],
  "hasTMAccessionNumbers": [
    "Y"
  ],
  "tmAccessionTypeList": [
    {
      "accessionType": [
        "nct"
      ]
    }
  ],
  "dateOfCreation": [
    "2020-06-17"
  ],
  "firstIndexDate": [
    "2020-06-17"
  ],
  "fullTextReceivedDate": [
    "2020-06-07"
  ],
  "dateOfRevision": [
    "2020-07-01"
  ],
  "electronicPublicationDate": [
    "2020-06-04"
  ],
  "firstPublicationDate": [
    "2020-06-04"
  ]
}